Document Type

Article

Publication Date

7-6-2023

Comments

This article is the author's final published version in Vaccines, Volume 11, Issue 7, 2023, Article number 1212.

The published version is available at https://doi.org/10.3390/vaccines11071212. Copyright © 2023 by the authors. Licensee MDPI, Basel, Switzerland.

Abstract

Onchocerciasis remains a debilitating neglected tropical disease. Due to the many challenges of current control methods, an effective vaccine against the causative agent Onchocerca volvulus is urgently needed. Mice and cynomolgus macaque non-human primates (NHPs) were immunized with a vaccine consisting of a fusion of two O. volvulus protein antigens, Ov-103 and Ov-RAL-2 (Ov-FUS-1), and three different adjuvants: Advax-CpG, alum, and AlT4. All vaccine formulations induced high antigen-specific IgG titers in both mice and NHPs. Challenging mice with O. volvulus L3 contained within subcutaneous diffusion chambers demonstrated that Ov-FUS-1/Advax-CpG-immunized animals developed protective immunity, durable for at least 11 weeks. Passive transfer of sera, collected at several time points, from both mice and NHPs immunized with Ov-FUS-1/Advax-CpG transferred protection to naïve mice. These results demonstrate that Ov-FUS-1 with the adjuvant Advax-CpG induces durable protective immunity against O. volvulus in mice and NHPs that is mediated by vaccine-induced humoral factors.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

vaccines-2470717-supplementary.pdf (383 kB)
Supplementary Materials

Language

English

Share

COinS